Abstract 2831
Background
The early complete morphological remission (CR) after induction chemotherapy is a major independent prognostic factor for both achievements of CR and long-term outcome in acute myeloid leukemia. we studied the correlation between the serum IL-6 levels and the early morphological CR aiming to use serum level of IL-6 instead of invasive painful BM aspiration as a predictive factor for the early response to induction chemotherapy in AML patients.
Methods
During the study period from February 2015 to May 2016, we investigate 36 patients. Eligibility criteria were the evidence of a diagnosis of AML (not AML-M3), both sexes, age of 18-60 years, Patients with a performance status of 0 to 2, and adequate organs functions. We excluded 6 ineligible patients from the study. All patients received induction chemotherapy of cytarabine and anthracycline in the standard “7 + 3” regimen. We did day 14 BM aspiration to detect the presence of early morphological complete remission (≤ 5% marrow blasts) and blood sampling for measurement of the interleukin-6 at presentation and day 14 of starting of induction chemotherapy.
Results
This study included eligible 30 newly diagnosed AML patients with age ranged from 18-60 years (Mean ± SD, 39.53 ± 13.54). The range of marrow blasts at presentation was 20-93% with the Mean ± SD of 58.10% ± 23.10%. As regards the levels of IL-6 at presentation, the mean ± SD was 42.46 ± 28.10 pg/ml and the range was 21.3 - 140.6. Day 14 BMA revealed 8 out of the 30 enrolled patients achieved complete morphological remission (≤ 5 % marrow blasts). There was a statistically significant decrease in IL-6 serum level in patients achieved morphological CR (mean + SD, 18.26 ± 5.75; range, 10.7 - 28.9 pg/ml) than those did not (mean + SD, 26.07 ± 4.78; range, 21.3 - 32.7 pg/ml) (P = 0.017). At Day 14 of induction chemotherapy, there was a significant positive correlation between IL-6 and marrow blasts (r = 0.745, P = 0.000*).
Conclusions
Interleukin-6 is suggested to be a good predictive marker for early response to induction chemotherapy in patients with acute myeloblastic leukemia and may be used instead of invasive day 14 BM aspiration as a marker of this response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Assiut University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract